CNMD · CONMED Corporation

Current Thesis

CONMED Corporation's sale-premium thesis failed its published price test on 2026-09-18; a disclosed transaction would establish a new deal case, but cannot reverse that recorded invalidation. The adjusted Friday close of $45.42 was below the $46 weekly-close condition published on 2026-09-05. The narrative is dead in its previously published price-supported form — that classification follows the September 18 breach, without establishing that a corporate sale process has ended.

The original narrative rests on the 2026-07-10 media report that CONMED was considering a sale. Management subsequently discussed operating growth and acquisition capacity at the 2026-09-09 Wells Fargo conference, without announcing a bidder, transaction agreement or sale timetable in that transcript. Operating commentary has advanced; the reported sale remains unresolved. September 9 conference transcript

Bullish and bearish views on CONMED Corporation

The model's bull view on CONMED Corporation (CNMD), in brief: Management supplied a fresh operating case. The bear view: The published structure has failed. The 2026-09-18 adjusted close of $45.42 crossed below the previously published $46 weekly-close threshold. The earlier thesis cannot remain open simply because the July sale report remains unresolved. Headline earnings included a refund. The… Both cases follow in full.

Bull Case

• Management supplied a fresh operating case. On 2026-09-09, Chief Financial Officer John Gallagher described second-half organic constant-currency revenue growth guidance of 6%–8% and expected further AirSeal acceleration. That expectation would fail its operating test if second-half growth falls below 6%. Conference transcript
• Underlying sales growth remains measurable. CONMED's 2026-07-29 release reported second-quarter sales of $343.5 million, up 0.3% as reported and 6.0% excluding currency movements and exited gastroenterology products. Those results provide evidence for an operating recovery, although they do not establish acquisition interest. Second-quarter results

Bear Case

• The published structure has failed. The 2026-09-18 adjusted close of $45.42 crossed below the previously published $46 weekly-close threshold. The earlier thesis cannot remain open simply because the July sale report remains unresolved.
• Headline earnings included a refund. The 2026-07-29 earnings call attributed $0.21 per share of second-quarter adjusted earnings to a tariff refund absent from guidance. Third-quarter adjusted earnings per share guidance was $0.98–$1.03, against the second-quarter result of $1.38; the refund limits the usefulness of that headline comparison.
• New research does not establish terms. Argus published a quantitative report lowering its target to $49 on 2026-09-09. This updates the earlier account of analyst silence, but an analyst valuation supplies no bidder, consideration or transaction timetable. Argus report distributed by Yahoo Finance

Setup & Price Structure

The supplied adjusted daily series records a $45.42 close on 2026-09-18, a three-month price increase of 39.6%, and a 14-period relative strength index (RSI) of 19.6. The positive trailing return coexists with weak recent momentum. These measurements do not establish a reversal or support a probability estimate for a rebound.

Coverage has changed since the September 5 note: MarketBeat records a Weiss Ratings upgrade to Hold on 2026-09-17, alongside the September 9 Argus report. These are observable research events, not evidence of widening investor participation. Ratings history

CONMED's filing index also lists a Form 4 dated 2026-09-10. The index alone does not establish whether the underlying transaction was a discretionary sale, purchase or award. No dated moving-average series, short-interest observation or retail-flow measure is available here; the evidence is insufficient to characterize crowding. Company filing index

Catalyst Calendar (next 30 days)

• 2026-09-19 through 2026-10-19: No company-confirmed catalyst was established for this window in the available disclosures. The sale report dated 2026-07-10 provides no scheduled resolution date.
• ~2026-11-03, estimated: ChartMill currently lists third-quarter results for this date; issuer confirmation was not established. This later operating checkpoint tests the 2026-07-29 guidance of $334–$339 million in sales and $0.98–$1.03 in adjusted earnings per share. It is not a confirmed deadline for the reported sale process. Vendor earnings calendar

What Would Change Our Mind

Loss of the published price structure has already occurred: a weekly close below $46 was the thesis-break condition, and the 2026-09-18 close of $45.42 satisfied it. Lowering the threshold would change the original test after the outcome.

A company-disclosed definitive agreement with stated consideration would supply evidence for a separate transaction thesis. A company announcement ending consideration of a sale would instead resolve the remaining uncertainty against the July report's upside interpretation. The operating alternative has its own observable test: third-quarter sales below the $334 million lower end of July 29 guidance would contradict the projected acceleration.

Correlation Notes

The analytical frame remains a single-company special situation because the original catalyst was CONMED-specific sale reporting on 2026-07-10. At the September 9 conference, management described AirSeal, BioBrace and international expansion as operating drivers; these connect the business to surgical activity, but do not establish stock-return correlation with a medtech group. No matched sector-return sample is available to support a correlation claim. Conference transcript